

[] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person *				2.	Issuer Name and Ticker or Trading Symbol							5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
ZASLOFF MICHAEL A					Amphastar Pharmaceuticals, Inc. [AMPH]								_X_ Director		10%	6 Owner	
(Las	(Last) (First) (Middle)				3. Date of Earliest Transaction (MM/DD/YYYY)							Officer (giv	e title below	() Oth	er (specify b	pelow)	
C/O AMPHASTAR					6/7/2021												
PHARMAC 6TH STREI		ALS, IN	C., 1157	70													
(Street)				4.	4. If Amendment, Date Original Filed (MM/DD/YYYY)							6. Individual or Joint/Group Filing (Check Applicable Line)					
RANCHO CUCAMONGA, CA 91730 (City) (State) (Zip)				30								X _ Form filed by One Reporting Person Form filed by More than One Reporting Person					
	219) (8			- Non-De	riva	tive Secu	ırities Ac	equire	ed, D	isposed	l of, c	or Bei	neficially Owne	ed			
1. Title of Security (Instr. 3)			. Trans. Date	Exe	Deemed cution e, if any	3. Trans. C (Instr. 8)	ode	or Di	or Disposed of (D)		F	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)			Form: Beneficial	7. Nature of Indirect Beneficial Ownership	
					Code	V	Amo	unt (A)		Price				or Indirect (I) (Instr. 4)			
Common Stock 6/7/202				6/7/2021			A		6019	<u>(1)</u> A	S	\$0.00	47206			D	
	Ta	ıble II - De	erivative S	Securities	Ben	eficially	Owned	(e.g.,	puts	, calls, v	warr	rants,	options, conver	tible secu	urities)		
1. Title of Derivate Security (Instr. 3)	Conversion or Exercise Price of Derivative	3. Trans. Date	3A. Deeme Execution Date, if any	(Instr. 8)	Code	Derivative Acquired (Disposed of	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date		Sec		nderlying Derivative ecurity Security		9. Number of derivative Securities Beneficially Owned	Form of Derivative Security:	11. Nature of Indirect Beneficial Ownership (Instr. 4)
	Security			Code	V	(A)	(D)	Date Exerci	isable	Expiratio Date	n Titl	le	Amount or Number of Shares		Following Reported Transaction(s) (Instr. 4)	Direct (D) or Indirect (I) (Instr. 4)	
Stock Option (right to buy)	\$19.52	6/7/2021		A		17182		<u>(2</u>	<u>2)</u>	6/7/2029		ommon Stock	17182	\$0	17182	D	

Explanation of Responses:

- (1) The reported shares are represented by restricted stock units, or RSUs, all of which vest on June 7, 2022.
- (2) All of the shares subject to the option vest on June 7, 2022.

Reporting Owners

reporting Owners							
Reporting Owner Name / Address	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
ZASLOFF MICHAEL A							
C/O AMPHASTAR PHARMACEUTICALS, INC.	v						
11570 6TH STREET	Λ						
RANCHO CUCAMONGA, CA 91730							

Signatures

/s/ Eva Wen, by power of attorney

**Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.